1AI 0.00% 1.0¢ algorae pharmaceuticals limited

this poster session breaks out the UPDRS data....

  1. 54 Posts.
    this poster session breaks out the UPDRS data.
    http://www.lctglobal.com/upload/art...ongress NTCELL abstract poster 2016 final.pdf

    in hindsight, i should have paid more attention to this statement "
    The lack of change in dopamiergic
    PET measures as reported at the 2015
    meeting indicates that any improvement
    is not related to resprouting of nigrostriatal
    dopaminergic nerve terminals. Efficacy
    could be the result of recovery in function
    of other types of neurons involved in
    neurodegeneration and compensatory
    mechanisms known to occur"

    In addition, if you look at the pdq-39 graph, which i believe is data from a questionaire filled out by patients, there was littl change at 81weeks from baseline in 2 of the patients and at 132weeks there is even less.

    this is cherry picking on my part by only pointing out this one document and i do respect dr barry snow, with his experience in transplantation in pd i have to believe he was sincerely convinced they were on to something, he was well aware of past transplantation trials that had great open label phase1 results and negative phase2 results when the trial was blinded and controlled. look at this youtube video where he describes many previous trials, including a porcine study which had very similar outcome to LCT's phase1 and phase2b trials.

    his discussion starts around 35minutes.
    title:
    Parkinson’s Auckland presents Dr Barry Snow

    the phase1 graph is very similar to the LCT phase1 graph.


    i have to say though that i think the company overhyped the expected outcome more than any other company doing a pd phase2b trial involving transplants. just my opinion, hindsight is 20/20.

    PDQ-39
    There are 39 questions in the long form Parkinson’s Disease Questionnaire, with 8 discrete scales:
    • mobility (10 items)
    • activities of daily living (6 items)
    • emotional well-being (6 items)
    • stigma (4 items)
    • social support (3 items)
    • cognitions (4 items)
    • communication (3 items)
    • bodily discomfort (3 items)
    Patients are asked to think about their health and general well-being and to consider how often in the last month they have experienced certain events (e.g. difficulty walking 100 yards). Patients are asked to indicate the frequency of each event by selecting one of 5 options (likert Scale): never/occasionally/sometimes/often/always or cannot do at all.

    https://innovation.ox.ac.uk/outcome-measures/parkinsons-disease-questionnaire-pdq-39-pdq-8/
 
watchlist Created with Sketch. Add 1AI (ASX) to my watchlist
(20min delay)
Last
1.0¢
Change
0.000(0.00%)
Mkt cap ! $16.61M
Open High Low Value Volume
1.0¢ 1.0¢ 1.0¢ $1.15K 115.0K

Buyers (Bids)

No. Vol. Price($)
12 5779455 0.9¢
 

Sellers (Offers)

Price($) Vol. No.
1.0¢ 1750608 7
View Market Depth
Last trade - 16.10pm 29/03/2024 (20 minute delay) ?
Last
0.9¢
  Change
0.000 ( 10.0 %)
Open High Low Volume
1.0¢ 1.0¢ 0.9¢ 480000
Last updated 15.47pm 29/03/2024 ?
1AI (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.